Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase I Study of PM14 in Advanced Solid Tumors
NCT05076396Phase 1Completed
- Sponsor
- PharmaMar
- Start
- Sep 2017
- Primary completion
- Aug 2025
- Modality
- Small Molecules
- Countries
- 3
01
Overview
Phase 1, open-label, single-arm trial of ecubectedin in solid tumor, sponsored by PharmaMar. Primary endpoints: Dose Limiting Toxicities at 3 weeks and Overall Response Rate at 27 weeks. Started Sep 2017; status: completed.
02
Drugs
ecubectedin
03
Conditions
solid tumor
Beyond the preview
Go deeper on NCT05076396.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05076396.